Stability and Biological Testing of taurine-conjugated Bile Acid Antioxidant Microcapsules for Diabetes Treatment

References

• Gaull GE Wright CE . Taurine conjugation of bile acids protects human cells in culture . Adv. Exp. Med. Biol.217 , 61 – 67 ( 1987 ).
   PubMedGoogle Scholar
• Fritzsch B Neubert RH Dongowski G Heinevetter L . Interactions between food components and drugs. Part 8: effect of pectins and bile acid preparations forming stable mixed micelles on transport of quinine in vitro . Pharmazie55 ( 1 ), 59 – 61 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Houten SM Watanabe M Auwerx J . Endocrine functions of bile acids . Embo. J.25 ( 7 ), 1419 – 1425 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Wey HE Yunker RL Harris P Subbiah MT . Effect of streptozotocin-induced diabetes in neonatal rat on bile acid pool changes in adult life: selective sensitivity in females . Biochem. Med.31 ( 2 ), 167 – 173 ( 1984 ).
   PubMedGoogle Scholar
• Watanabe M Horai Y Houten SM et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure . J. Biol. Chem.286 ( 30 ), 26913 – 26920 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Brinton EA . Novel pathways for glycaemic control in Type 2 diabetes: focus on bile acid modulation . Diabetes Obes. Metab.10 ( 11 ), 1004 – 1011 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Beysen C Murphy EJ Deines K et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in Type 2 diabetes: a randomised controlled study . Diabetologia55 ( 2 ), 432 – 442 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Nunez DJ Yao X Lin J et al. Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with Type 2 diabetes subjects taking metformin . Diabetes Obes. Metab.18 ( 7 ), 654 – 662 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Lee E Kim YS Bae SM et al. Polyproline-type helical-structured low-molecular weight heparin (LMWH)–taurocholate conjugate as a new angiogenesis inhibitor . Int. J. Cancer124 ( 12 ), 2755 – 2765 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Khatun Z Nurunnabi M Reeck GR Cho KJ Lee YK . Oral delivery of taurocholic acid linked heparin–docetaxel conjugates for cancer therapy . J. Control. Rel.170 ( 1 ), 74 – 82 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Engin F Yermalovich A Nguyen T et al. Restoration of the unfolded protein response in pancreatic beta cells protects mice against type 1 diabetes . Sci. Transl. Med.5 ( 211 ), 211ra156 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Mathavan S Chen-Tan N Arfuso F Al-Salami H . A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes . Drug Deliv.23 ( 8 ), 2869 – 2880 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Mooranian A Negrulj R Arfuso F Al-Salami H . The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study . Drug Deliv. Transl. Res.5 ( 5 ), 511 – 522 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Negrulj R Mooranian A Chen-Tan N et al. Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes . Artif. Cells Nanomed. Biotechnol.44 ( 5 ), 1290 – 1297 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Mooranian A Negrulj R Arfuso F Al-Salami H . Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: formulation characterization and effects on production of insulin and inflammation in a pancreatic beta-cell line . Artif. Cells Nanomed. Biotechnol.44 ( 7 ), 1642 – 1653 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Mooranian A Negrulj R Mikov M Golocorbin-Kon S Arfuso F Al-Salami H . Novel chenodeoxycholic acid–sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study . J. Microencapsul.32 ( 6 ), 589 – 597 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Negrulj R Mooranian A Chen-Tan N et al. Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes . Artif. Cells Nanomed. Biotechnol.44 ( 5 ), 1290 – 1297 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Mooranian A Negrulj R Chen-Tan N et al. Novel multicompartmental bile acid-based microcapsules for pancreatic beta-cell transplantation . Xenotransplantation22 , S93 – S94 ( 2015 ).
   Web of Science ®Google Scholar
• Mooranian A Negrulj R Al-Sallami HS et al. Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in Type 2 diabetes . AAPS PharmSciTech.16 ( 1 ), 45 – 52 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Mooranian A Negrulj R Chen-Tan N et al. Microencapsulation as a novel delivery method for the potential antidiabetic drug, probucol . Drug Des. Devel. Ther.8 , 1221 – 1230 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hamaguchi K Gaskins HR Leiter EH . NIT-1, a pancreatic beta-cell line established from a transgenic NOD/Lt mouse . Diabetes40 ( 7 ), 842 – 849 ( 1991 ).
   PubMed Web of Science ®Google Scholar
• Mooranian A Negrulj R Al-Salami H . The effects of ionic gelation-vibrational jet flow technique in fabrication of microcapsules incorporating β-cell: applications in diabetes . Curr. Diabetes Rev.13 ( 1 ), 91 – 96 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Mooranian A Negrulj R Chen-Tan N Watts GF Arfuso F Al-Salami H . An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer . Drug Des. Devel. Ther.8 , 1673 – 1683 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Mooranian A Negrulj R Mathavan S et al. An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug–bile acid formulations . Pharm. Dev. Technol.20 ( 6 ), 702 – 709 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Mooranian A Negrulj R Al-Sallami HS et al. Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment . J. Microencapsul.32 ( 2 ), 151 – 156 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Mooranian A Negrulj R Mathavan S et al. Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics . J. Pharm. Innov.99 , 150 – 157 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Goto S Kawata M Nakamura M Nagatsuma Y Fujinaga K Aoyama T . Evaluation of the sustained release properties of Eudragit RS, RL and S (acrylic resins) microcapsules containing ketoprofen in beagle dogs . J. Microencapsul.5 ( 4 ), 343 – 360 ( 1988 ).
   PubMed Web of Science ®Google Scholar
• Benita S Hoffman A Donbrow M . Polyacrylate resin (Eudragit retard) microcapsules as a controlled release drug delivery system-improved non-solvent addition phase separation process . J. Microencapsul.2 ( 3 ), 207 – 222 ( 1985 ).
   PubMedGoogle Scholar
• Mathavan S Mikov M Golocorbin-Kon S Al-Salami H . Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects . Eur. J. Pharm. Sci.106 , 1 – 9 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Mooranian A Negrulj R Al-Salami H . Viability and topographical analysis of microencapsulated β-cells exposed to a biotransformed tertiary bile acid: an ex vivo study . Int. J. Nano Biomater.6 ( 2 ), ( 2016 ). 10.1504/IJNBM.2016.079684 .
   Google Scholar
• Mooranian A Zamani N Takechi R et al. Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of Type 1 diabetes . Artif. Cells Nanomed. Biotechnol. doi:10.1080/21691401.2018.15115721 – 7 ( 2018 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Mooranian A Zamani N Mikov M et al. Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid . Ther. Deliv.9 ( 11 ), 811 – 821 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Mooranian A Zamani N Mikov M et al. Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses . Artif. Cells Nanomed. Biotechnol. doi:10.1080/21691401.2018.15115711 – 7 ( 2018 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Mooranian A Negrulj R Takechi R Mamo J Al-Sallami H Al-Salami H . The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects . Drug Deliv. Transl. Res.8 ( 3 ), 543 – 551 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Mamo JC Lam V Brook E et al. Probucol prevents blood–brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet . Diab. Vasc. Dis. Res. doi:10.1177/1479164118795274 1479164118795274 ( 2018 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Mamo JC Lam V Al-Salami H et al. Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflammation and neurodegeneration . Ther. Deliv.9 ( 10 ), 703 – 709 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Takechi R Lam V Brook E et al. Blood–brain barrier dysfunction precedes cognitive decline and neurodegeneration in diabetic insulin resistant mouse model: an implication for causal link . Front. Aging Neurosci.9 , 399 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Kruyt ND Van Westerloo DJ Devries JH . Stress-induced hyperglycemia in healthy bungee jumpers without diabetes due to decreased pancreatic beta-cell function and increased insulin resistance . Diabetes Technol. Ther.14 ( 4 ), 311 – 314 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Farina M Campos F Vendrell I et al. Probucol increases glutathione peroxidase-1 activity and displays long-lasting protection against methylmercury toxicity in cerebellar granule cells . Toxicol. Sci.112 ( 2 ), 416 – 426 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Naito M Umegaki H Iguchi A . Protective effects of probucol against glutamate-induced cytotoxicity in neuronal cell line PC12 . Neurosci. Lett.186 ( 2-3 ), 211 – 213 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Negre-Salvayre A Alomar Y Troly M Salvayre R . Ultraviolet-treated lipoproteins as a model system for the study of the biological effects of lipid peroxides on cultured cells. III. The protective effect of antioxidants (probucol, catechin, vitamin E) against the cytotoxicity of oxidized LDL occurs in two different ways . Biochim. Biophys. Acta1096 ( 4 ), 291 – 300 ( 1991 ).
   PubMedGoogle Scholar